Cadila Pharma inaugurates Greenfield API manufacturing plant at Dahej

Set up with an investment of Rs. 200 crore, the state-of-the-art facility is equipped with the latest Distributed Control System (DCS) automation technology.

Dr. HG Koshia, Commissioner of Food and Drugs Control Administration (FDCA), Gujarat, and Dr. MP Nakrani, Assistant Commissioner of FDCA, Bharuch Circle, graced the inauguration ceremony with their presence.

Dr. Koshia said, “It is truly a pleasure to visit Cadila Pharmaceuticals’ state-of-the-art API project at Dahej. It is a great moment for me, and my tribute to the legendary Pharma Man of India and catalyst of the Gujarat Pharma industry, Late Shri IA Modi. I feel and sense his presence by visiting such a beautiful creation. We miss his presence, but under his guidance and able leadership, Cadila Pharmaceuticals has created a unique API plant that will serve humankind for many years by producing quality APIs.”

Speaking on the occasion, Biswajit Mitra, Chief Mentoring Officer at Cadila Pharmaceuticals, said, “This state-of-the-art API manufacturing facility at Dahej represents our commitment to providing high-quality, cost-effective APIs to our customers worldwide. The DCS technology used in this facility will allow us to produce APIs with a high level of purity and consistency, while also reducing the environmental impact. This facility is designed to be highly efficient, aiding us in meeting the growing demand for our products. I am confident this facility will play a key role in our future success.”

Cadila Pharmaceuticals had earlier signed an MoU with the government of Gujarat for investing Rs. 1,000 crore in Gujarat. The Dahej API facility is one of the projects for which the MoU was signed.

The new API manufacturing facility will enable Cadila Pharmaceuticals to provide customers with quality products, while also helping it to expand its reach into new markets.

The facility incorporates advanced Distributed Control System technology, enhancing greater precision and efficiency in the production process. The facility is designed with a focus on sustainable practices, aligning with Cadila Pharmaceuticals’ broader environmental initiatives and reflects its commitment to advancing healthcare solutions through cutting-edge technology and sustainable practices.